Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
IPO Year: 1981
Exchange: NASDAQ
Website: csi360.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $15.00 | Equal Weight | Barclays |
| 12/14/2022 | $25.00 | Buy | Lake Street |
| 3/2/2022 | $22.00 | Underperform | BofA Securities |
| 2/4/2022 | $25.00 → $20.00 | Outperform | SVB Leerink |
| 11/17/2021 | Buy → Hold | Needham | |
| 11/10/2021 | Buy → Neutral | Guggenheim | |
| 11/10/2021 | $45.00 → $40.00 | Outperform | SVB Leerink |
| 9/23/2021 | $50.00 → $49.00 | Buy | Needham |
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)
15-12G - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)
MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am
Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $15.00
Lake Street initiated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $25.00
BofA Securities resumed coverage of Cardiovascular Systems with a rating of Underperform and set a new price target of $22.00
SVB Leerink reiterated coverage of Cardiovascular Systems with a rating of Outperform and set a new price target of $20.00 from $25.00 previously
Needham downgraded Cardiovascular Systems from Buy to Hold
Guggenheim downgraded Cardiovascular Systems from Buy to Neutral
SVB Leerink reiterated coverage of Cardiovascular Systems with a rating of Outperform and set a new price target of $40.00 from $45.00 previously
Needham reiterated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $49.00 from $50.00 previously
Barclays initiated coverage of Cardiovascular Systems with a rating of Equal-Weight
Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $43.00
NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C
Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin
Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla
KAIZEN to assess safety and efficacy of peripheral orbital atherectomy to secure regulatory approval in Japan Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD). The study is intended to support regulatory approval in Japan. The first KAIZEN patient was enrolled by Tatsuya Nakama, M.D., Vice Director, Department of
System includes mechanical and aspiration thrombectomy devices to treat peripheral vascular disease Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that Innova Vascular, Inc. (Innova) has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease. Thrombectomy is a rapidly growing interventional procedure performed to remove blood clots from arteries and veins. CSI intends to acquire and commercialize each of th
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management plans to present and host investor meetings at the Stifel 2022 Healthcare Conference and will host investor meetings at the Canaccord Genuity MedTech Conference. Stifel 2022 Healthcare Conference Wednesday, November 16, 2022 1:15 p.m. ET Webcast Canaccord Genuity MedTech Conference Thursday, November 17, 2022 About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing an
Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor
Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown). Built on the proven Diamondback 360® Orbital Atherectomy platform, the 2.00 Max Crown is uniquely designed to enable simultaneous modification of both intimal and medial calcium. The new 2.00 Max Crown features an increased 70-micron diamond coated crown that creates more efficient engagement in mixed plaque, helping to achieve optimal luminal gain in mild to moder
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) plans to announce its operating results for the quarter ended September 30, 2022 before the market opens on Thursday, November 3, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to participate in the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats c
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
4 - Cardiovascular Systems Inc (0001180145) (Issuer)
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin
Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla
Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) plans to announce its operating results for the quarter ended September 30, 2022 before the market opens on Thursday, November 3, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to participate in the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats c
Webcast of Capital Markets Day on August 3 will include discussion of fiscal fourth-quarter results Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets day on August 3. The webcast of the capital markets day will begin on Wednesday, August 3, 2022, at 9:00 a.m. CT (10:00 a.m. ET). To access the live webcast click here. A webcast replay will be available later the same day. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device c
Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 revenue guidance narrowed to $235 million to $240 million Announced partnership with Innova Vascular, Inc. to develop full line of thrombectomy devices Announced first in-human experience with peripheral everolimus drug-coated balloon Completed first in-human experience with Propel™ percutaneous ventricular assist device Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative int
Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) plans to announce its operating results for the quarter ended March 31, 2022 before the market opens on Wednesday, May 4, 2022, and will host a conference call at 8:00 a.m. CT (9:00 a.m. ET) that day to discuss those results. To access the live webcast, please register for the webcast here. A webcast replay will be available later the same day. To participate in the conference call, please register for the conference call here. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coron
Conference Call Scheduled for Today, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $59.1 million increased 1.3% sequentially compared to first quarter this year and decreased 7.8% compared to second quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by Covid-19 Fiscal year 22 revenue guidance lowered to $235 million to $245 million Developing intravascular lithotripsy (IVL) technology for the treatment of coronary and peripheral artery diseases Scoreflex® NC scoring balloon received FDA PMA approval Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing in
Live Webcast at 8:00 a.m. CT (9:00 a.m. ET) Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII) will host a live webcast of its fiscal 2022 second-quarter conference call on Thursday, February 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET). CSI management will discuss results for its fiscal second quarter ended December 31, 2021, and its financial outlook. CSI will issue an earnings release prior to the call on February 3, 2022. To access the live webcast, please register for the webcast here. A webcast replay will be available later the same day. To participate in the conference call, please register for the conference call here. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc.,
Conference Call Scheduled for Today, November 9, 2021, at 8:00 AM CT (9:00 AM ET) Revenues of $58.4 million decreased 3.6% compared to first quarter last year Procedure volumes adversely impacted by hospital constraints and staffing shortages caused by the COVID-19 Delta variant Management provides updated fiscal year 2022 revenue guidance of $265 million to $285 million, representing 2% to 10% growth First in human experience with everolimus coronary drug coated balloon First patient treated with ViperCross™ peripheral support catheter First patients in Canada treated with Diamondback 360® Coronary OAS Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device com